S. Mark Tompkins, Ph.D.
|B.S. Microbiology||University of Illinois||Urbana, IL||1990|
|Ph.D. Immunology||Emory University||Atlanta, GA||1997|
- Post-doctoral Experience
- Postdoctoral Associate, Immunology, Northwestern University Medical School, Chicago, IL, 1997-2002
Postdoctoral Associate, Virology/Immunology, CBER/FDA, Bethesda, MD, 2002-2005
- Honors and Awards
- 2012-2013 2012 Fulbright Senior Scholar, Australian-American Fulbright Commission
Fellows Award for Research Excellence (FARE), National Institutes of Health Fellows Committee, the Scientific Directors, the Office of Research on Women's Health, and the NIH Office of Education, Bethesda, MD. Protection against lethal influenza virus challenge by RNA interference in vivo, 2004
John M. Bowen Award for Excellence in Animal/Biomedical Research, University of Georgia College of Veterinary Medicine, 2007
- Research Interests
- Dr. Tompkins' research interests focus on understanding transmission and pathogenicity of zoonotic influenza virus infection and development of novel approaches to vaccination and the prevention and treatment of viral infections. This utilizes a variety of animal models and disease hosts including mice, ferrets, cats, and swine. Studies include understanding transmission and pathogenic potential of avian influenza virus field isolates, surveillance of non-contemporary mammalian influenza viruses, mutagenesis of influenza viruses, novel recombinant vaccine and vaccine delivery development, therapeutic applications of RNA interference, and understanding the role of microRNAs in infectious disease and neoplasia. Related to this he has contributed to genome-wide screening for host genes involved in viral (influenza, measles, RSV, polio, Hendra) replication using siRNA libraries. He has also worked on a variety of approaches for development of human antibodies for prevention and treatment of infectious diseases. Recent studies explore the innate immune response to viral infection is different host species, including human, swine, mouse, feline, alligator, and bat. As a Fulbright Scholar, he focused on identification of drug targets and development of novel anti-viral drugs for Hendra virus and other emerging infectious diseases.
- Representative Publications
- Mooney, A., Li, Z., Gabbard, J.D., He, B., and S.M. Tompkins. 2013 Recombinant PIV5 vaccine protects against HPAI H5N1 infection when delivered intranasally or intramuscularly. J. Virol. 87(1):363-71. PMID: 23077318
Perwitasari, O., Bakre, A., Tompkins, S.M., and R.A. Tripp. 2013 siRNA Genome Screening Approaches to Therapeutic Drug Repositioning. Pharmaceuticals. 6(2):124-160.
Perwitasari, O. Torrecilhas, A.C., Yan, X., Johnson, S., White, C., Tompkins, S.M., and R.A. Tripp. 2013 Targeting Cell Division Cycle 25 Homolog B (CDC25B) to Regulate Influenza Virus Replication. J Virol. 2013 Oct 9. [Epub ahead of print] PMID: 24109234
McCutcheon, K.M., Gray, J., Chen, N.Y., Liu, K., Park, M., Ellsworth, S., Tripp, R.A., Tompkins, S.M., Johnson, S.K., Samet, S., Pereira, L., Kauvar, L.M. 2014 Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets. MAbs. 6(2):460-73. PMID: 24492306.
Fox J.M., Sage L.K., Poore, S., Johnson, S., Tompkins S.M., Tripp R.A. Drug analog inhibition of indoleamine 2,3-dioxygenase (IDO) activity modifies pattern recognition receptor expression and proinflammatory cytokine responses early during influenza virus infection. J Leukoc Biol. 2014 May 5. PMID: 24799604